NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.65 -0.15 (-2.21 %) (As of 07/18/2018 12:42 PM ET)Previous Close$6.85Today's Range$6.65 - $6.8552-Week Range$1.50 - $10.65Volume30,126 shsAverage Volume2.62 million shsMarket Capitalization$796.92 millionP/E RatioN/ADividend YieldN/ABeta2.47 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California. Receive SRNE News and Ratings via Email Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:SRNE CUSIPN/A Webwww.sorrentotherapeutics.com Phone858-203-4100 Debt Debt-to-Equity Ratio0.02 Current Ratio0.71 Quick Ratio0.71 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$151.85 million Price / Sales5.06 Cash Flow$0.2174 per share Price / Cash30.59 Book Value$2.50 per share Price / Book2.66 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$9.13 million Net Margins23.25% Return on Equity21.91% Return on Assets8.31% Miscellaneous Employees162 Outstanding Shares115,500,000Market Cap$796.92 Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions What is Sorrento Therapeutics' stock symbol? Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE." How were Sorrento Therapeutics' earnings last quarter? Sorrento Therapeutics Inc (NASDAQ:SRNE) issued its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. Sorrento Therapeutics had a net margin of 23.25% and a return on equity of 21.91%. View Sorrento Therapeutics' Earnings History. What price target have analysts set for SRNE? 5 brokerages have issued 1 year target prices for Sorrento Therapeutics' stock. Their forecasts range from $7.00 to $40.00. On average, they anticipate Sorrento Therapeutics' share price to reach $15.45 in the next year. This suggests a possible upside of 129.9% from the stock's current price. View Analyst Ratings for Sorrento Therapeutics. What is the consensus analysts' recommendation for Sorrento Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Sorrento Therapeutics? Sorrento Therapeutics saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 19,659,939 shares, an increase of 21.9% from the June 15th total of 16,123,092 shares. Based on an average trading volume of 3,653,853 shares, the days-to-cover ratio is currently 5.4 days. Approximately 22.5% of the shares of the stock are short sold. View Sorrento Therapeutics' Current Options Chain. Who are some of Sorrento Therapeutics' key competitors? Some companies that are related to Sorrento Therapeutics include BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO) and BIOQUAL (BIOQ). Who are Sorrento Therapeutics' key executives? Sorrento Therapeutics' management team includes the folowing people: Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)Dr. Jerome Bernard Zeldis, Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)Dr. Alexis Nahama, VP of Corp. Devel. Has Sorrento Therapeutics been receiving favorable news coverage? News articles about SRNE stock have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sorrento Therapeutics earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. How do I buy shares of Sorrento Therapeutics? Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sorrento Therapeutics' stock price today? One share of SRNE stock can currently be purchased for approximately $6.72. How big of a company is Sorrento Therapeutics? Sorrento Therapeutics has a market capitalization of $796.92 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe. How can I contact Sorrento Therapeutics? Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected] MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)Community Ranking: 3.5 out of 5 ( )Outperform Votes: 352 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?